-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 2017, Luxturna, the first gene therapy for the treatment of hereditary retinal dystrophy, was approved by the FDA to target inherited Retinal Diseases (IRDs)
Vision "stolen" by time – a mouse model of neovascular macular degeneration (AMD).
Figure 1 Schematic diagram of hVEGF overexpressed mouse (TG) construction strategy
Figure 2 FFA (fundus fluorescence angiography) results
Saeye Bio Ophthalmic Gene Therapy Solutions
I sincerely hope that with the efforts of all parties, more gene therapy methods will enter clinical trials to help people with congenital blindness see the dawn
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.